BERTIS Inc. signs plasma proteome analysis MOU

with Seoul National University Hospital Gangnam Center

- Proteomic profiling in blood by gender and age group and joint research to discover protein biomarkers
- Seung-man Han, CEO of BERTIS Inc., says, "This agreement represents a significant opportunity

for the development of proteomics technology in Korea."

<Picture: CEO Seung-man Han, BERTIS Inc. (left), and Seoul National University Hospital Gangnam Center president Ju-seong Kim (right) take

a commemorative photo after signing a contactless business agreement.>

On April 28th, BERTIS Inc. a company that develops early-detection technology based on proteomics announced that it had signed a business agreement with Seoul National University Gangnam Center for plasma proteome analysis by gender and age group. 

Following this agreement, both organizations will profile blood proteomes and accelerate research to verify the clinical feasibility of individual health checks through the discovery and monitoring of protein biomarkers. To this end, both organizations have been made to plan to cooperate on ▲the collection of blood samples by gender and age group, ▲acquisition of previews and study consent forms of study subjects, ▲and processing and transport of collected samples.  

Through this MOU, BERTIS Inc. ultimately aims to change the paradigm of the diagnostics market by expanding its protein library, its greatest strength, and developing various technologies for disease diagnosis. After 10 years of research, BERTIS Inc. is now in possession of a protein library with 25 million entries and based on this, the speed of biomarker discovery has been dramatically reduced.

CEO Seung-man Han, BERTIS Inc. said that “It is expected to carry out the complicated work of proteomic profiling with more speed and efficiency with the help of Seoul National University Gangnam Center’s medical data and outstanding research competency” and that “in completing of this study, the company will secure unrivaled data and technology in the proteomics field, the future of diagnostics technology not only in Korea but also in the worldwide.”